Elite’s R&D pipeline includes two branded products and two generic products being developed in-house by Elite and two products being developed under contract with a partner. Elite’s lead product is sustained release oxycodone, a pain management product that is being developed with and without abuse resistance features.

One of the two products being developed under contract which launched in 2004 with the second product to be launched in 2005. One branded product and two generic products being developed in-house by Elite have all been evaluated in human studies. Elite also has a portfolio of additional projects that are in the research stage.

Elite develops products that have high barriers to entry with regard to factors such as:

        ►    Products with formulation complexities

        ►    Products with regulatory challenges

        ►    Products requiring specialized release profiles

        ►    Products with raw material problems

Elite typically develops these products through proof of concept and then partners or licenses them out to fund the further development and for marketing. Under licensing terms, Elite typically receives milestone payments during development and royalty payments upon commercialization.

Elite is a full service research and development company and can pursue an ANDA/ADA project from its inception through development and approval to launch stage.